Reported Earnings • May 22
First quarter 2026 earnings released: EPS: CA$0.004 (vs CA$0.001 in 1Q 2025) First quarter 2026 results: EPS: CA$0.004 (up from CA$0.001 in 1Q 2025). Revenue: CA$8.75m (up 11% from 1Q 2025). Net income: CA$145.3k (up 433% from 1Q 2025). Profit margin: 1.7% (up from 0.3% in 1Q 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 114 percentage points per year, which is a significant difference in performance. Valuation Update With 7 Day Price Move • Apr 23
Investor sentiment improves as stock rises 23% After last week's 23% share price gain to CA$1.75, the stock trades at a trailing P/E ratio of 36.1x. Average trailing P/E is 24x in the Consumer Retailing industry in Canada. Total returns to shareholders of 157% over the past three years. Reported Earnings • Apr 19
Full year 2025 earnings released: EPS: CA$0.05 (vs CA$0.023 in FY 2024) Full year 2025 results: EPS: CA$0.05 (up from CA$0.023 in FY 2024). Revenue: CA$35.8m (up 33% from FY 2024). Net income: CA$1.66m (up 135% from FY 2024). Profit margin: 4.6% (up from 2.6% in FY 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 109 percentage points per year, which is a significant difference in performance. Duyuru • Apr 15
Grey Wolf Animal Health Corp., Annual General Meeting, Jun 24, 2026 Grey Wolf Animal Health Corp., Annual General Meeting, Jun 24, 2026. Valuation Update With 7 Day Price Move • Feb 03
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to CA$1.50, the stock trades at a trailing P/E ratio of 62.1x. Average trailing P/E is 22x in the Consumer Retailing industry in Canada. Total returns to shareholders of 83% over the past three years. Reported Earnings • Nov 23
Third quarter 2025 earnings released: EPS: CA$0.02 (vs CA$0.016 in 3Q 2024) Third quarter 2025 results: EPS: CA$0.02 (up from CA$0.016 in 3Q 2024). Revenue: CA$9.34m (up 35% from 3Q 2024). Net income: CA$549.0k (up 9.3% from 3Q 2024). Profit margin: 5.9% (down from 7.3% in 3Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 18% per year but the company’s share price has increased by 13% per year, which means it is well ahead of earnings. Reported Earnings • Aug 25
Second quarter 2025 earnings released: EPS: CA$0.02 (vs CA$0.019 in 2Q 2024) Second quarter 2025 results: EPS: CA$0.02 (up from CA$0.019 in 2Q 2024). Revenue: CA$9.52m (up 32% from 2Q 2024). Net income: CA$751.2k (up 30% from 2Q 2024). Profit margin: 7.9% (down from 8.0% in 2Q 2024). The decrease in margin was driven by higher expenses. Valuation Update With 7 Day Price Move • Jun 13
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to CA$1.10, the stock trades at a trailing P/E ratio of 62.1x. Average trailing P/E is 23x in the Consumer Retailing industry in Canada. Total returns to shareholders of 77% over the past year. Reported Earnings • May 23
First quarter 2025 earnings released: EPS: CA$0.001 (vs CA$0.004 in 1Q 2024) First quarter 2025 results: EPS: CA$0.001 (down from CA$0.004 in 1Q 2024). Revenue: CA$7.92m (up 31% from 1Q 2024). Net income: CA$27.2k (down 78% from 1Q 2024). Profit margin: 0.3% (down from 2.1% in 1Q 2024). The decrease in margin was driven by higher expenses. New Risk • Apr 22
New major risk - Financial position The company's debt is not well covered by operating cash flow. Operating cash flow to total debt ratio: 6.5% This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (6.5% operating cash flow to total debt). Minor Risk Market cap is less than US$100m (CA$32.5m market cap, or US$23.5m). Reported Earnings • Apr 20
Full year 2024 earnings released: EPS: CA$0.02 (vs CA$0.02 in FY 2023) Full year 2024 results: EPS: CA$0.02 (in line with FY 2023). Revenue: CA$26.8m (up 5.6% from FY 2023). Net income: CA$704.7k (up 16% from FY 2023). Profit margin: 2.6% (up from 2.4% in FY 2023). The increase in margin was driven by higher revenue. Duyuru • Apr 14
Grey Wolf Animal Health Corp., Annual General Meeting, Jun 19, 2025 Grey Wolf Animal Health Corp., Annual General Meeting, Jun 19, 2025. Valuation Update With 7 Day Price Move • Dec 05
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to CA$1.09, the stock trades at a trailing P/E ratio of 40.4x. Average trailing P/E is 22x in the Pharmaceuticals industry in Canada. Total loss to shareholders of 41% over the past three years. New Risk • Dec 03
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 10% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Profit margins are more than 30% lower than last year (3.5% net profit margin). Shareholders have been diluted in the past year (10% increase in shares outstanding). Market cap is less than US$100m (CA$34.9m market cap, or US$24.8m). Reported Earnings • Nov 22
Third quarter 2024 earnings released: EPS: CA$0.02 (vs CA$0.009 in 3Q 2023) Third quarter 2024 results: EPS: CA$0.02 (up from CA$0.009 in 3Q 2023). Revenue: CA$6.90m (up 5.7% from 3Q 2023). Net income: CA$502.2k (up 78% from 3Q 2023). Profit margin: 7.3% (up from 4.3% in 3Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 63% per year but the company’s share price has fallen by 22% per year, which means it is significantly lagging earnings. New Risk • Nov 12
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Canadian stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Profit margins are more than 30% lower than last year (2.7% net profit margin). Market cap is less than US$100m (CA$26.4m market cap, or US$18.9m). Duyuru • Oct 30
Grey Wolf Animal Health Announces Launch of SILEO Grey Wolf Animal Health Corp. announced the Canadian commercial launch of SILEO® (dexmedetomidine hydrochloride oromucosal gel) to veterinary clinics throughout Canada. SILEO builds on Grey Wolf's portfolio dedicated to behaviour and anxiety health in companion animals. Dogs that experience fear and anxiety in response to loud noise such as fireworks now have a new treatment option. SILEO is available from veterinarians by prescription and can be administered at home by pet owners to help calm dogs without sedation. Reported Earnings • Aug 22
Second quarter 2024 earnings released: EPS: CA$0.02 (vs CA$0.006 in 2Q 2023) Second quarter 2024 results: EPS: CA$0.02 (up from CA$0.006 in 2Q 2023). Revenue: CA$7.20m (up 7.7% from 2Q 2023). Net income: CA$577.5k (up 188% from 2Q 2023). Profit margin: 8.0% (up from 3.0% in 2Q 2023). The increase in margin was driven by higher revenue. Buy Or Sell Opportunity • Aug 12
Now 21% undervalued after recent price drop Over the last 90 days, the stock has fallen 15% to CA$0.61. The fair value is estimated to be CA$0.77, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 8.0% over the last year. Meanwhile, the company has become profitable. Reported Earnings • May 24
First quarter 2024 earnings released: EPS: CA$0.004 (vs CA$0.013 in 1Q 2023) First quarter 2024 results: EPS: CA$0.004 (down from CA$0.013 in 1Q 2023). Revenue: CA$6.05m (flat on 1Q 2023). Net income: CA$126.1k (down 69% from 1Q 2023). Profit margin: 2.1% (down from 6.8% in 1Q 2023). Board Change • May 21
High number of new and inexperienced directors There are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. 1 highly experienced director. Independent Director Rob Harris is the most experienced director on the board, commencing their role in 2016. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Apr 12
Full year 2023 earnings released: EPS: CA$0.02 (vs CA$0.15 in FY 2022) Full year 2023 results: EPS: CA$0.02 (down from CA$0.15 in FY 2022). Revenue: CA$25.4m (up 12% from FY 2022). Net income: CA$609.6k (down 76% from FY 2022). Profit margin: 2.4% (down from 11% in FY 2022). The decrease in margin was driven by higher expenses. Duyuru • Apr 12
Grey Wolf Animal Health Corp., Annual General Meeting, Jun 19, 2024 Grey Wolf Animal Health Corp., Annual General Meeting, Jun 19, 2024. Reported Earnings • Nov 24
Third quarter 2023 earnings released: EPS: CA$0.01 (vs CA$0.078 loss in 3Q 2022) Third quarter 2023 results: EPS: CA$0.01 (up from CA$0.078 loss in 3Q 2022). Revenue: CA$6.53m (up 12% from 3Q 2022). Net income: CA$282.5k (up CA$1.43m from 3Q 2022). Profit margin: 4.3% (up from net loss in 3Q 2022). The move to profitability was primarily driven by higher revenue. Duyuru • Nov 02
Murray Roach to Leave Grey Wolf Animal Health Corp. as Chief Commercial Officer Grey Wolf Animal Health Corp. announced that effective October 31, 2023 Murray Roach, Chief Commercial Officer, has decided to leave Grey Wolf. Reported Earnings • Aug 29
Second quarter 2023 earnings released: EPS: CA$0.01 (vs CA$0.075 loss in 2Q 2022) Second quarter 2023 results: EPS: CA$0.01 (up from CA$0.075 loss in 2Q 2022). Revenue: CA$6.68m (up 8.8% from 2Q 2022). Net income: CA$200.5k (up CA$1.30m from 2Q 2022). Profit margin: 3.0% (up from net loss in 2Q 2022). The move to profitability was primarily driven by lower expenses. Reported Earnings • Jun 01
First quarter 2023 earnings released: EPS: CA$0.013 (vs CA$0.072 loss in 1Q 2022) First quarter 2023 results: EPS: CA$0.013 (up from CA$0.072 loss in 1Q 2022). Revenue: CA$6.04m (up 7.0% from 1Q 2022). Net income: CA$410.5k (up CA$1.47m from 1Q 2022). Profit margin: 6.8% (up from net loss in 1Q 2022). The move to profitability was primarily driven by lower expenses. Reported Earnings • Apr 26
Full year 2022 earnings released Full year 2022 results: Revenue: CA$22.6m (up 73% from FY 2021). Net income: CA$2.54m (up CA$3.51m from FY 2021). Profit margin: 11% (up from net loss in FY 2021). The move to profitability was driven by higher revenue. Reported Earnings • Dec 03
Third quarter 2022 earnings released Third quarter 2022 results: CA$1.30 loss per share. Net loss: CA$1.14m (flat on 3Q 2021). Duyuru • Nov 29
Grey Wolf Animal Health Corp. Announces Board Changes Grey Wolf Animal Health Corp. announced that on November 15, 2022, the company completed the previously announced qualifying transaction with Magen Ventures I Inc. In connection with the completion of the qualifying transaction, the Company is also announcing (i) the resignation of Jolyon Burton, and (ii) the appointment of Jill Angevine and Diane Bourassa to Grey Wolf's Board of Directors as independent directors. Ms. Angevine is a finance professional with more than 25 years of experience in the investment management industry including portfolio management, capital markets and equity research. She currently serves as President and CEO of Brownstone Asset Management, a private investment firm, and holds non-executive directorships at additional public companies in the energy and mining sectors. Ms. Angevine holds a Bachelor of Commerce degree from the University of Calgary and has earned the Chartered Public Accountant (CPA, CA), the Chartered Financial Analyst (CFA), and the Institute of Corporate Directors (ICD.D) designations. Ms. Bourassa is a visionary business leader with extensive operational and financial expertise. Throughout her 30-year career, Ms. Bourassa succeeded in developing highly competitive and performing teams. Determined to share her skills and boundless energy with other companies, she has been focused since January 2022 on strategic consulting, individual coaching, and business development services. Ms. Bourassa worked for 14 years in the Canadian subsidiary of Vetoquinol S.A. Her leadership as General Manager of Vetoquinol Canada from 2011 to 2021 propelled Vetoquinol into the top 5 animal health pharmaceutical companies in Canada. Ms. Bourassa was a member of the Board of Directors of the Canadian Animal Health Institute for a period of 10 years, where she held various positions, including Chair of the Board of Directors from 2015 to 2016. Ms. Bourassa started her career at Ernst & Young and holds a CPA, CA designation. Board Change • Nov 25
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Founder, Director & CVMO Ian Sandler was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. 